RenovoRx achieved key milestones in the commercial launch of RenovoCath in 2025, its first full year of generating revenue with a growing adoption of TAMP enabled by RenovoCath in cancer centers throughout the United States, with early commercial traction reflecting increasing physician interest in targeted intra-arterial drug-delivery. RenovoRx estimates that the initial total addressable market (TAM) for RenovoCath as a stand-alone device represents an approximately $400 million peak annual U.S. sales opportunity, and ultimately a multi-billion-dollar potential as the platform expands into additional solid tumor indications.
Cyborg Score Rationale
The company was recognized as number 10 in the medical device category on Fast Company's prestigious list of the World's Most Innovative Companies of 2026. In its first full year of commercial efforts, RenovoRx generated approximately $1.1 million in RenovoCath sales, demonstrating early traction. However, the company faces biotech execution risk with clinical trials and commercialization challenges.
Top Insights
The RenovoTAMP therapy is being studied in the Phase III TIGeR-PaC trial for the treatment of locally advanced pancreatic cancer.
In its first full year of commercial efforts, RenovoRx generated approximately $1.1 million in RenovoCath sales with several customers already initiating repeat orders and the number of medical institutions initiating new RenovoCath orders expanding, including several esteemed, high-volume National Cancer Institute-designated centers.
RenovoRx's patent portfolio includes seven U.S. patents for its technology and the Company has secured two separate Orphan Drug Designations from the FDA for intra-arterial gemcitabine including pancreatic cancer and bile duct cancer.
RenovoRx secured approximately $10 million through a private placement with institutional investors in March 2026.
Named Competitors
Varian — Radiation therapy for cancer treatment
Gemcitabine (Systemic) — Standard systemic chemotherapy for pancreatic cancer